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 Current guidelines support the well-established clinical prac-
tice that patients who present with atrial fi brillation (AF) of 
less than 48 hours duration should be considered for cardio-
version, even in the absence of pre-existing anticoagulation. 
However, with increasing evidence that short runs of AF confer 
signifi cant risk of stroke, on what evidence is this 48-hour rule 
based and is it time to adopt a new approach? We review 
existing evidence and suggest a novel approach to risk strati-
fi cation in this setting. Overall, the risk of thromboembolism 
associated with acute cardioversion of patients with AF that 
is estimated to be of <48 hours duration is low. However, this 
risk varies widely depending on patient characteristics. From 
existing evidence, we show that using the CHA 2 DS 2 -VASc score 
may allow better selection of appropriate patients in order to 
prevent exposing specifi c patient groups to an unacceptably 
high risk of a potentially devastating complication. 
 KEYWORDS :  Anticoagulants ,  atrial fi brillation ,  cardioversion ,  electri-
cal cardioversion ,  stroke ,  thromboembolism 
 Introduction 
 International guidelines support the well-established clinical 
practice that patients who present with non-valvular atrial 
fibrillation (AF) of less than 48 hours duration should be 
considered for cardioversion, even in the absence of pre-existing 
anticoagulation. 1,2 The risk with more prolonged periods of AF 
is that restoration of sinus rhythm may precipitate embolism of 
intra-atrial thrombus causing stroke. However, with increasing 
evidence that even short runs of AF confer significant risk of 
stroke, 3–6 this review examines the evidence supporting the ‘48-
hour rule’ and suggests a novel approach to risk stratification in 
this setting. 
 Search strategy and selection criteria 
 Data for this review were identified by searches of PubMed 
using combinations of the terms ‘atrial fibrillation’, 
‘cardioversion’ and ‘thromboembolism’. References sourced 
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from relevant articles were also included. Additional references 
were identified from review of current international guidelines 
on the management of atrial fibrillation. 1,2 
 Is duration of AF predictive of stroke risk? 
 Both paroxysmal and persistent AF increase the risk of 
ischaemic stroke. 7 However, the risk is greater in patients 
with persistent arrhythmia (unadjusted annual risk of 2.1% 
compared to 1.5%) 8,9 implying that the duration of AF is an 
important factor in determining stroke risk. Boriani  et al 
examined data from over 10,000 patients with implanted 
cardiac devices to determine the critical burden (ie the duration 
and frequency) of paroxysmal AF that was needed to confer 
stroke risk. 10 Overall they found that the relative risk of stroke 
increased by 3% for each additional hour of maximal daily 
AF burden. However, the threshold of AF burden that was 
associated with the highest relative risk for ischaemic stroke was 
1 hour (hazard ratio (HR) 2.11; 95% CI 1.22–3.64, p=0.008. 
They also found that AF was commonly asymptomatic, a 
finding supported by other studies with one highlighting 
that even in patients with AF lasting >48 hours, 17% were 
asymptomatic. 3,11 Therefore, if AF is commonly asymptomatic, 
and even paroxysms of AF lasting 1 hour confer a significant 
stroke risk, is duration of AF the best criteria for deciding 
whether or not to offer acute cardioversion? 
 Risk of thromboembolism following cardioversion – 
where does the 48-hour rule come from? 
 The ‘48-hour rule’ was adopted into widespread clinical practice 
based on theoretical, rather than evidence-based, grounds. 
This practice was scrutinised by Weigner  et al in 1997. 12 It was 
known that cardioversion of patients with AF of >48 hours 
duration had a 5–7% risk of stroke without preceding 
anticoagulation. 12 However, it was also known that 14% of 
patients with AF of <72 hours duration would have atrial 
thrombi detectable on transoesophageal echo (TOE). 13 Weigner 
 et al prospectively examined 375 patients admitted with 
symptomatic AF lasting <48 hours in order to determine the 
incidence of cardioversion-related clinical thromboembolism. 
A total of 357 patients converted to sinus rhythm during 
admission, of which 66.7% did so without pharmacological 
or electrical attempts at rhythm control. Overall, only 3 
(0.8%) patients suffered a thromboembolic event, none of 
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whom had been actively cardioverted. The authors concluded 
that early cardioversion of patients with AF of <48 hours 
duration was safe. This conclusion has been supported by 
several other observational studies that found the risk of 
thromboembolism to be negligible (ranging from 0–0.9%) 
in patients who undergo cardioversion for AF of <48 hours 
from symptom onset. 14–20 More recently, the Fin-CV study 
examined over 3,000 patients with AF of estimated duration 
<48 hours who were cardioverted by either pharmacological 
or electrical intervention. 21 They confirmed that overall the 
risk of cardioverting patients with AF of <48 hours was low 
(0.7%), with 38 thromboembolic events occurring within 
30 days following cardioversion. However, this risk varied 
greatly depending on patient factors (Fig  1 ), such that risk was 
unacceptably high at 9.8% if a patient had heart failure and 
diabetes, compared with 0.2% in patients aged less than 60 
years without heart failure. Interestingly, a subgroup analysis 
of this study found that even within 48 hours, the risk of 
thromboembolism varied with the duration of AF, from 0.3% 
if the patient was cardioverted within 12 hours compared with 
1.1% beyond 12 hours (Fig  2 ). 22 
 Strategies to reduce the risk of thromboembolism 
associated with cardioversion 
 Out-with the emergency setting (Box  1 ), acute cardioversion 
is a semi-elective procedure with an established alternative 
strategy (ie elective cardioversion after 4 weeks of reliable 
anticoagulation) and so only minimal levels of risk should be 
accepted. The authors of the Fin-CV study advocate that their 
results support the use of routine anticoagulation following 
cardioversion, especially in high-risk patients. However, with 
the majority of thromboembolic events occurring shortly after 
cardioversion (median 2 days), it could be argued that these 
high-risk patients should not be treated with cardioversion at all, 
at least not until they are established on reliable anticoagulation 
or a TOE has excluded intra-cardiac thrombus. 23 A sustained 
period of anticoagulation prior to cardioversion is established 
practice in patients with AF >48 hours, with some evidence to 
support its efficacy. 1,2,15,17,23 Alternatively, TOE has been shown 
to be as good as 3 weeks of anticoagulation at reducing the risk of 
thromboembolism following cardioversion. 23 TOE in this setting 
has the advantage of fewer haemorrhagic events, faster time to 
cardioversion and greater success rate at restoring sinus rhythm 
(presumably because of the earlier intervention) compared with 
patients treated with anticoagulation. 23 However, these benefits 
must be balanced against the invasive nature of a TOE, as well as 
cost implications and resource constraints. 
 A novel strategy for risk stratification: using CHA 2 DS 2 -
VASc 
 The Fin-CV study examined patient specific risk factors 
and found that age, diabetes, female sex and heart failure 
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 Fig 1.  Embolic risk following cardioversion depends on CHA 2 DS 2 -VASc score . A – the absolute number of cardioversions performed without complication 
(blue) and with embolic complications (red) in patients with increasing CHA 2 DS 2 -VASc scores; B – the percentage of cardioversions with embolic complications 
in patients with increasing CHA 2 DS 2 -VASc scores. Data from  Airaksinen et al . 
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 Fig 2.  The effects of duration of atrial fi brillation (AF) and CHA 2 DS 2 -
VASc score on the occurrence of embolic complications following 
cardioversion . Dark blue bars show embolic complications for patients 
cardioverted within 12 hours from onset of AF and light blue bars show 
those patients cardioverted 12–48 hours after onset of AF. Data from  Nuotio 
et al . 22 
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were all independent predictors of thromboemoblic risk. 
Unsurprisingly, they found the CHA 2 DS 2 -VASc score of 
thromboembolic risk, which was developed to identify 
long-term risk of stroke in patients with AF, 24 to be ‘highly 
predictive’ of thromboembolism in the acute setting. Even 
for patients within 48 hours of symptom onset, the risk of 
thromboembolism following cardioversion varied by a factor 
of 10 from 0.35% to 3.5% for a CHA 2 DS 2 -VASc score of ≤2 
compared with a score of >5 (Fig  1 ). Similarly, a study that 
examined the risk of thromboembolism with and without 
anticoagulation in 16,000 patients who underwent electrical 
cardioversion for either acute (<48 hours) or chronic AF 
(>48 hours) also found that increasing CHA 2 DS 2 -VASc 
score was associated with increasing thromboembolic risk 
(HR for thromboembolism within 30 days was 6.86 (95% 
CI 1.55–30.37) for CHA 2 DS 2 -VASc of 2 compared to 0). 
25 
Because all patients with a new diagnosis of AF should have 
their CHA 2 DS 2 -VASc score calculated in order to assess their 
long-term risk of thromboemoblism, 1 it could also be used in 
the acute setting, in conjunction with duration of symptoms, 
when determining a patient’s suitability for acute cardioversion. 
There is, however, no prospective trial data to support this 
recommendation. Furthermore, even using a CHA 2 DS 2 -VASc 
score cut-off of 1 would still miss 26% of the thromboembolic 
events in the Fin-CV study, while in the same study there were 
over 2,000 cardioversions performed without complication 
in patients with a CHA 2 DS 2 -VASc score ≥2. This might be 
partly explained by the effect of AF duration on embolic risk 
(Fig  2 ) or the different weightings of individual components of 
CHA 2 DS 2 -VASc, and two patients with a score of 2 would have 
very different risk profiles if one had diabetes and heart failure, 
while the other had hypertension and vascular disease. 21 
 The role of anticoagulation peri-cardioversion 
 International guidelines differ slightly with regards to the 
requirement of anticoagulation peri-cardioversion. 1,2,26 
The National Institute for Health and Care Excellence 
advises using CHA 2 DS 2 -VASc score to assess stroke risk in 
patients with ‘continuing risk of arrhythmia recurrence after 
cardioversion back to sinus rhythm’. 26 This advice is similar 
to the current European and American guidelines, which 
state that the decision regarding long-term anticoagulation 
after cardioversion should be guided by the patient’s 
thromboembolic risk, regardless of the duration of AF 
prior to cardioversion. 1,2 Where the guidelines differ is that 
the European guidelines state that all patients undergoing 
cardioversion should have a minimum of 4 weeks of 
anticoagulation, whereas the American guidelines advise 
that in patients who have had AF <48 hours and have a 
low thromboembolic risk you can consider not prescribing 
anticoagulation at all. The rationale for anticoagulating all 
patients after cardioversion is to minimise the risk associated 
with ‘atrial stunning’, which promotes formation of left atrial 
thrombus subjecting the patient to a transient increase in their 
baseline risk. 21,27,28 This is supported by data from Hansen  et al , 
who found that the benefit of anticoagulation following direct 
current cardioversion was maintained regardless of the patient’s 
CHA 2 DS 2 -VASc score. While patients with a higher CHA 2 DS 2 -
VASc score were more likely to develop a thromboembolic 
complication, the relative benefit of anticoagulation was the 
same irrespective of baseline risk: anticoagulation reduced 
the risk of thromboembolism by half even in patients with 
a CHA 2 DS 2 -VASc of 1. However, it should be noted that this 
study included patients with AF >48 hours (in whom current 
guidelines would not recommend cardioversion without a 
period of preceding anticoagulation). Furthermore, although 
the relative risk reduction is maintained, the absolute risk 
of thromboembolism in patients with CHA 2 DS 2 -VASc of 
1, especially if cardioverted within 48 hours, is very low. 
Therefore, the absolute benefit is likely to be small and must be 
balanced against the small risk of 4 weeks of anticoagulation. 
The study of Hansen  et al also found that there was no 
difference in the benefit of anticoagulation in patients who 
received it both pre- and post-procedure compared with those 
that received anticoagulation either pre-procedure or post-
procedure only. Another study, which retrospectively analysed 
567 cardioversions within 48-hours of onset, found benefit of 
post-procedure anticoagulation with a fivefold greater risk in 
those that did not receive anticoagulation after cardioversion. 
In this study, no thromboembolic events occurred in patients 
with a CHA 2 DS 2 -VASc <2 in either group. 
29 
 Is acute rhythm control worth the risk? 
 Overall, the risk of thromboembolism that is associated 
with acute rhythm control in appropriate patients is very 
low (0–0.9%). 14–20 Early rhythm control has the advantage 
of faster outcomes, improved symptom control and reduced 
hospital stay. 30,31 Furthermore, the longer a patient has AF, 
the more difficult it is to achieve successful cardioversion to 
sinus rhythm. 32 While some observational data 8,9 supports the 
pursuit of rhythm control because of a reduced risk of stroke in 
patients with paroxysmal (as opposed to persistent) AF, this has 
not been replicated in clinical trials. Several studies (including 
the landmark AFFIRM trial) 33 have shown that there is no 
difference in survival or thromboembolism in patients with 
AF who are treated with rhythm control as opposed to rate 
control. 33–38 
 Is there a difference in thromboembolic risk between 
electrical and pharmacological cardioversion? 
 There is evidence supporting the safety and efficacy of 
both direct current cardioversion and pharmacological 
cardioversion. 16,21,39 Analysis of the RHYTHM-AF international 
registry of cardioversion found no difference in the rate of 
thromboembolism following electrical versus pharmacological 
cardioversion in 3,940 patients (0.26% versus 0.39%, 
respectively). 16 In the Fin-CV study, there was no statistical 
Box 1. Emergency cardioversion
Patients who present with adverse features – such as 
haemodynamic compromise, syncope, mycocardial ischaemia 
or acute pulmonary oedema – that are believed to be as a 
result of, or exacerbated by, the patient’s atrial fibrillation 
should receive urgent cardioversion regardless of the duration 
of atrial fibrillation or anticoagulation status.1,2 All patients who 
receive emergency cardioversion should be anticoagulated for a 
minimum of 4 weeks afterwards if no contraindications.2
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comparison of electrical versus pharmacological cardioversion; 
however, 36 of the 38 thromboembolic complications occurred 
in patients treated with electrical cardioversion (accounting 
for a rate of 0.81% of all cardioversions or 1.65% of all patients 
treated with electrical cardioversion compared with rates 
of 0.32% and 0.67% for the corresponding figures in the 
pharmacological group). Electrical cardioversion has the risks 
associated with sedation, post-cardioversion bradycardia and 
skin burns. 1 On the other hand, electrical cardioversion has 
been shown to be more effective – achieving sinus rhythm 
in 89% of patients compared with 69% of patients treated 
pharmacologically. 16 
 Conclusions 
 Overall the risk of thromboembolism associated with acute 
cardioversion of patients with AF that is estimated to be of 
<48 hours duration is low. However, this risk varies widely 
depending on patient characteristics. Current guidelines 
expose some patients to an unacceptably high risk of 
thromboembolism. In our opinion, when considering and 
gaining consent from patients for acute cardioversion for AF 
of <48 hours and who are not established on anticoagulation, 
clinicians should be aware of a patient's individual 
thromboembolic risk (eg CHA 2 DS 2 -VASc) and if the duration 
of arrhythmia exceeds 12 hours from symptom onset. If both 
of these criteria suggest an increased risk, we would advise 
proceeding with caution. This strategy adds an additional 
safeguard to avoid exposing some patients to an unacceptably 
high risk of a potentially devastating complication from a 
non-emergency procedure. The risk of thromboembolism 
following cardioversion is not immediate and can persist for 
30 days. Post-procedure anticoagulation reduces this risk. 
Anticoagulation should continue lifelong in patients with 
conventional thromboembolic risk factors (CHA 2 DS 2 -VASc 
>1). For low risk patients, international guidelines vary 
regarding the need for 4 weeks of anticoagulation post-
procedure, but this should be considered and discussed with 
the patient. ■ 
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